Search results
Apr 4, 2024 · COVID Variant JN. 1. Currently, COVID JN. 1 is the most prevalent variant. According to the Centers for Disease Control and Prevention (CDC), as of March 2024, this variant accounted for over 95%...
5 days ago · As of 3 March 2023, ECDC has de-escalated BA.2, BA.4 and BA.5 from its list of SARS-CoV-2 variants of concern (VOC), as these parental lineages are no longer circulating. ECDC will continue to categorise and report on specific SARS-CoV-2 sub-lineages in circulation that are relevant to the epidemiological situation.
Mar 31, 2024 · From May 2021 onwards, WHO began assigning simple, easy-to-say labels for key variants. Considerable progress has been made in establishing and strengthening a global system to detect signals of potential VOIs or VOCs and rapidly assess the risk posed by SARS-CoV-2 variants to public health.
Apr 17, 2024 · COVID-19 Variant Update. 17 April, 2024. As of April 17, 2024, the SARS-CoV-2 Omicron variant JN.1 has very high prevalence in the United States, with CDC Nowcast projections estimating JN.1 to account for more than 95% of all COVID-19 illnesses in the US.
Apr 19, 2024 · The CDC says the updated vaccines should also work against currently circulating variants of the SARS-CoV-2 virus—many of which descended from, or are related to, the XBB strain. The vaccine is also expected to protect against JN.1, the current dominant strain in the U.S.
Apr 12, 2024 · In this edition, we include: • The COVID-19 epidemiological update at the global and regional levels. • An update on hospitalizations and ICU admissions. • An update on the SARS-CoV-2 variants of interest (VOI) and variants under monitoring (VUM).
1 day ago · The objective of an update to COVID-19 vaccine antigen composition is to enhance vaccine-induced immune responses to circulating SARS-CoV-2 variants. As the virus is expected to continue to evolve from JN.1, the TAG-CO-VAC advises the use of a monovalent JN.1 lineage as the antigen in future formulations of COVID-19 vaccines.
